Table 2.
Disease response (as-treated population).
| MEDI0680 + durvalumab (n = 42) | Nivolumab (n = 21) | |
|---|---|---|
| Best overall response, n (%) | ||
| Complete response | 2 (4.8) | 0 |
| Partial response | 5 (11.9) | 5 (23.8) |
| Stable disease | 17 (40.5) | 8 (38.1) |
| Unconfirmed partial response | 2 (4.8) | 0 |
| Progressive disease | 17 (40.5) | 6 (28.6) |
| Not evaluable | 1 (2.4) | 2 (9.5) |
| Objective response, n (%) | 7 (16.7) | 5 (23.8) |
| 95% CI | 7.0–31.4 | 8.2–47.2 |
| P valueb | 0.513 | — |
| Median progression-free survival (95% CI), months | 3.6 (2.0–5.5) | 3.6 (1.9–13.0) |
| Median overall survival (95% CI), months | NR (NR–NR) | NR (12.0–NR) |
| Median time to response (range), months | 1.8 (1.7–12.8) | 1.8 (1.6–7.3) |
| Median duration of response (range), months | NR (9.5–23.5) | NR (1.9–9.2) |
| Disease control at ≥ 24 weeks, n (%)a | 16 (38.1) | 8 (38.1) |
| 95% CI | 23.6–54.4 | 18.1–61.6 |
Abbreviations: CI, confidence interval; NR, not reached.
aComplete and partial responses plus stable disease.
bAs compared with nivolumab.